Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Rationale The availability of the highly selective and specific kappa opioid agonist enadoline provides an opportunity to explore the function of kappa receptors in humans and their potential utility as a target for substance abuse pharmacotherapy development.Objectives The purpose of this study was to characterize the pharmacodynamic effects of enadoline, a selective kappa agonist, and to compare it with butorphanol, a mixed mu/kappa agonist, and hydromorphone, a mu agonist, in humans.Methods Pilot evaluation (n=3) served to establish intramuscular doses of enadoline (20, 40, 80, and 160 microg/70 kg), butorphanol (1.5, 3, 6, and 12 mg/70 kg), and hydromorphone (1.5, 3, and 6 mg/70 kg) of comparable activity. These acute doses were examined under double-blind, placebo-controlled and constrained randomized conditions with a minimum of 72 h between tests in volunteers with polysubstance abuse histories (n=6). Physiological and subject- and observer-rated measures were collected 30 min before and for 4 h after administration.Results Enadoline significantly increased measures of sedation, confusion and dizziness, produced visual distortions and feelings of depersonalization, and increased urinary output. The highest dose (160 microg/70 kg) was not tolerated and led to psychotomimetic effects. Hydromorphone produced prototypic mu opioid effects including respiratory depression, miosis, and euphoria. Butorphanol was most similar to hydromorphone and shared few effects with enadoline.Conclusions These results are discussed with respect to the potential use and safety of kappa agonists for clinical indications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A kappa-opioid receptor agonist, enadoline, increased feelings of depersonalization in a small sample of individuals with histories of substance abuse [112].”
From Treatment of dissociative identity disorder: leveraging neurobiology to optimize success (2024) · cites this paper as [112]
Citations
Cites
Opioid analgesics and antagonists
Reisine, T. (1996) · Medical Entomology and Zoology · Cited by 1,205
Martin, W. R., Sloan, J. W., Sapira, J. D., & Jasinski, D. R. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part1245 · Cited by 943
Psychotomimesis Mediated by κ Opiate Receptors
Pfeiffer, A., Brantl, V., Herz, A., & Emrich, H. M. (1986) · Science · doi:10.1126/science.3016896 · Cited by 857 · cited 3×
“These adverse effects have led some researchers to classify kappa agonists as psychotomimetics ( Pfeiffer et al. 1986 ) and have contributed to the failure of some of these agents in clinical trials.”
BackgroundResultInfluentialInteractions between Kappa Opioid Agonists and Cocaine: Preclinical Studies
Mello, N. K., & Negus, S. S. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06678.x · Cited by 247
The reinforcing and subjective effects of morphine in post-addicts: a dose-response study.
Lamb, R. J., Preston, K. L., Schindler, C. W., Meisch, R. A., Davis, F., Katz, J. L., Henningfield, J. E., & Goldberg, S. R. (1991) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20504-3 · Cited by 245 · cited 1×
“whereby morphine is perceived as dysphoric in drug-naive individuals but euphorigenic in experienced users ( Lamb et al. 1991; Zacny et al. 1994a).”
BackgroundFraser, H. F., Van Horn, G. D., Martin, W. R., Wolbach, A. B., & Isbell, H. (1961) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)26118-3 · Cited by 232
Assessment of the Abuse Potentiality of Morphinelike Drugs (Methods Used in Man)
Jasinski, D. R. (1977) · Drug Addiction I · doi:10.1007/978-3-642-66612-4_4 · Cited by 200
Hill, J. L., & Zacny, J. P. (2000) · Psychopharmacology · doi:10.1007/s002130000500 · Cited by 195 · cited 2×
“For example, human drug discrimination studies report that the subjective effects of butorphanol are more kappa-like than mu-like (Preston et al. 1989; Preston and Bigelow 1994; see Dykstra et al. 1997 for review) and a direct dosing study suggests that butorphanol can be readily differentiated from a pure mu agonist…”
BackgroundSelectivity of Ligands for Opioid Receptors
Corbett, A. D., Paterson, S. J., & Kosterlitz, H. W. (1993) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-77460-7_26 · Cited by 184 · cited 1×
“Enadoline is a potent compound which binds with high affinity to kappa sites (Ki=0.11 nM) and is estimated to be 900- and 9000-fold more selective for kappa over mu and delta opiate receptors, respectively (Clark et al. 1988; Boyle et al. 1990; Corbett et al. 1993 ).”
BackgroundInfluentialDykstra, L. A., Gmerek, D. E., Winger, G., & Woods, J. H. (1987) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39097-x · Cited by 168
Cited by
Items 201–269 of 269
Vázquez-León, P., Miranda-Páez, A., Sánchez-Castillo, H., & Marichal‐Cancino, B. A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00522-z · Cited by 6
“In humans, KOR agonists at high doses produce adverse effects such as fatigue, confusion, anxiety, hallucinations, and feelings of deper-sonalization [18, 19].”
Halberstadt, A. L., Hyun, J. S., Ruderman, M. A., & Powell, S. B. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.05.009 · Cited by 5
“Selective KOR agonists, such as salvinorin A and enadoline, produce profound dissociative effects and hallucinations in humans (Walsh et al., 2001; Johnson et al., 2011; Addy, 2012; Ranganathan et al., 2012; MacLean et al., 2013).”
BackgroundPotential Novel Therapeutics for Bipolar Disorders
Machado‐Vieira, R., Manji, H. K., & Zarate, C. A. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_51 · Cited by 6
“One caveat, however, is that activation of these receptors may also induce psychotomimetic and dysphoric effects (Rimoy et al. 1994; Walsh et al. 2001), as well as increase risk for addictive behavior.”
BackgroundGordon, A. T., Levine, J. D., Dubois, M. Y., DʼAngelo, R., Conlon, A. M., Levacic, D., & Lebovits, A. (2007) · Pain Medicine · doi:10.1111/j.1526-4637.2006.00229.x · Cited by 5
Rush, C. R., Vansickel, A. R., & Stoops, W. W. (2011) · Wiley eBooks · doi:10.1002/9781118023150.ch14 · Cited by 6
Relevance of the Kappa Dynorphin System to Schizophrenia and Its Therapeutics
Abi‐Dargham, A. (2021) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20210015 · Cited by 5
The spiritual sense, prayer and traditional American Indian healing
Adams, J. D., Jr., & García, C. (2012) · TANG [HUMANITAS MEDICINE] · doi:10.5667/tang.2011.0012 · Cited by 4
“KOR agonists, such as enadoline, can induce locomotor impairment and psychotomimetic effects that could be life threatening (Walsh et al., 2001).”
BackgroundKappa opioid receptor mediated operant performance in male and female rats
Namchuk, A. B., Tsuda, M. C., Lucki, I., & Browne, C. A. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173847 · Cited by 3
Bland, K., Chen, C., Huang, P., Ho, C. K., Howe, T., Ocampo, K., Zhao, P., Creed, S. M., Noel-Torres, J., Riley, A. P., et al. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110316 · Cited by 4
Volf, A., Brust, T. F., Kobylski, R. R., Czekner, K. M., Stahl, E. L., Cameron, M. D., Trojniak, A. E., Wood, A. B., Aubé, J., & Bohn, L. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02372-8 · Cited by 4
Sélectivité fonctionnelle des ligands des récepteurs opiacés
Audet, N., Archer-Lahlou, É., Richard-Lalonde, M., & Piñeyro, G. (2010) · médecine/sciences · doi:10.1051/medsci/2010268-9734 · Cited by 6
“d’abus inférieur à celui produit par les ligands du MOR [10], mais les propriétés psychomimétiques de ces agonistes [12], le développement de tolérance [13] ainsi que leurs effets dysphoriques et anxiogènes [14] limitent leur utilisation clinique.”
BackgroundOpioid Peptide-Derived Analgesics
Schiller, P. W. (2008) · Springer eBooks · doi:10.1007/978-0-387-76678-2_22 · Cited by 4
Kappa Opioids: Problems and Opportunities in Analgesia
Butelman, E. R., & Kreek, M. J. (2013) · ACS symposium series · doi:10.1021/bk-2013-1131.ch013 · Cited by 4
Pre-clinical Anti-Addictive and Side-Effect profiles of Novel Kappa-opioid Agonists
Young, D. A. (2015) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17014103 · Cited by 2
Ruan, X., Hall, S. M., & Kaye, A. D. (2016) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2016.05.007 · Cited by 4
A Psychedelic Neurochemistry of TimePreprint
Dawson, K. A. (2005) · CogPrints (University of Southampton) · Cited by 3
Niu, Z., Brutiu, B. R., Riomet, M., Kaiser, D., & Maulide, N. (2025) · Angewandte Chemie · doi:10.1002/ange.202503750 · Cited by 1
The Potential Clinical Use of Opioid-Receptor-Modulating Drugs in Bipolar Disorder
Gefke, M., Wagner, C. B., McIntyre, R. S., & Vinberg, M. (2025) · CNS Drugs · doi:10.1007/s40263-025-01247-8 · Cited by 1
“…randomized study ( n = 12) on the effects of ĸ-receptor agonists on the effects of cocaine (not on patients with BD), the ĸ-receptor agonist enadoline reduced some of the euphoric effects of cocaine; however, higher doses caused symptoms such as visual distortions, confusion, and paranoia [63, 64].”
Towards a pharmacology of depersonalization
Sierra, M. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511730023.009 · Cited by 1
Vuckovic, S. M., Prostran, M. S., Ivanović, M., Todorović, Z., Stojanović, R., Nešić, Z., Matic, I., & Milovanović, S. R. (2004) · Vojnosanitetski pregled · doi:10.2298/vsp0404413v · Cited by 1
Utilization of carbon dioxide as a building block in synthesis of active pharmaceutical ingredients
Faisal, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99429-3.00021-7 · Cited by 1
Investigating the Effects of Novel Kappa Opioid Receptor Agonists on the Dopamine Transporter
Simonson, B. (2011) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.16985389.v1 · Cited by 3
“The KOPr agonist, enadoline, is tolerated well up to 80 μg/70 kg body weight, alone and in combination with cocaine (Walsh et al. 2001a; Walsh et al. 2001b), but enadoline did not alter drug seeking or taking behaviour (Walsh et al.”
BackgroundNovel Therapeutic Approaches for Treating Bipolar Disorder
Machado‐Vieira, R., Henter, I. D., Baumann, J., Latov, D. R., Wheeler‐Castillo, C., & Zarate, C. A. (2011) · Wiley eBooks · doi:10.1002/9780470975114.ch21 · Cited by 1
Behavioural Pharmacology of Novel Kappa Opioid Compounds
Morani, A. S. (2011) · Figshare · doi:10.26686/wgtn.17011409.v1
Ewald, A. W. M. (2016) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17148113 · Cited by 3
Potential Utility of Kappa Ligands in the Treatment of Mood Disorders
Carlezon, W. A., & Cohen, B. M. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-197-0_22 · Cited by 1
“In clinical studies of substance abusers, the kappa agonist enadoline was observed to reduce some of the effects of cocaine, but it, too, caused sedation, depersonalization, visual distortions, confusion and, at high doses, paranoia (65, 66 ).”
BackgroundNovel Therapeutic Strategies for Bipolar Disorder
Machado‐Vieira, R., Manji, H. K., & Zarate, C. A. (2010) · Wiley eBooks · doi:10.1002/9780470661277.ch30 · Cited by 1
Ioja, E. (2008) · SZTE Repository of Dissertations (University of Szeged)
Identification and characterization of diterpene synthases in the salvinorin A biosynthetic pathway
Mitchell, R. (2012) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/26417
The Synthesis and Pharmacological Evaluation of Salvinorin A Analogues as Opioid Receptor Probes
Lovell, K. M. (2011) · KU ScholarWorks (The University of Kansas)
Opioid Modulation of Voltage-Gated Calcium Currents
Soto, E., Seseña, E., & Vega, R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800634-4.00046-9
Preston, K. L., Schmittner, J. P., Epstein, D. H., & WALSH, S. L. (2007) · CRC Press eBooks · doi:10.1201/9781420054606.ch8
Self-citationSnyder, L. M., Omori, Y., Hachisuka, J., Adelman, P. C., Hu, Z., Fulton, S. A., Sypeck, E., Huang, H., Cai, X., Scherrer, G., et al. (2017) · Journal of Pain · doi:10.1016/j.jpain.2017.02.369
Atigari, D. V. (2019) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17136338.v1
“, 1986), sedation (Walsh et al., 2001), insomnia, and dysphoria (Glick et al.”
BackgroundInfluentialGENETIC SCREENING OF DRUG ADDICTION SUSCEPTIBILITY MARKERS
Jabeen, S. (2016) · Cited by 1
Chepur, S. V., Галан, С. Е., Vakhviayanen, M. S., Khromov, R. N., & Semenov, A. N. (2020) · Toxicological Review · doi:10.36946/0869-7922-2020-4-27-33
(2002) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.358
Fulton, B. S. (2014) · Wiley eBooks · doi:10.1002/9781118943670.refs
Heishman, S. J. (2006) · CRC Press eBooks · doi:10.1201/9781420003468.ch4
The pruritus of cholestasis: treatment options
Bergasa, N. V. (2007) · Springer eBooks · doi:10.1007/1-4020-2916-0_19
Berridge, K. C. (2008) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.1102183.558183
Feller, D. (2007) · xPharm: The Comprehensive Pharmacology Reference · doi:10.1016/b978-008055232-3.61459-x
McDonald, J., & Lambert, D. G. (2014) · BJA Education · doi:10.1093/bjaed/mku041
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00680-6
Abadey, A. A. (2023) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.23639313
A dynorphin theory of depression and bipolar disorder
Rappoport, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-44-345008-2.00010-2 · Cited by 1
Vandenbruggen, J., Ambros, B., Beaufrère, H., & Desprez, I. (2025) · Journal of Exotic Pet Medicine · doi:10.1053/j.jepm.2025.09.017
Social trauma and the mu-opioid system in depression
Malcolm‐Smith, S. (2011) · Open University of Cape Town (University of Cape Town)
Holguin, G., & Martin‐Fardon, R. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1729040 · Cited by 1
“…other KOP agonists, including enadoline and ketocyclazocine, induced visual distortions, dissociation, and dysphoric states (Kumor et al., 1986; Walsh et al., 2001), further indicating a pivotal role of the DYN/KOP system in mediating dysphoria and negative affect across species, contributing…”
Contextual Influences on Naltrexone Sensitization During Daily Morphine Exposure
Paronis, C. A., & Bergman, J. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.104311
Шагиахметов, Ф. Ш., Krupitsky, E. M., Shamakina, I. Y., Anokhin, P. K., Arkus, M. L., & Scheidegger, Y. M. (2026) · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY · doi:10.31363/2313-7053-2026-1-1179
The Dynorphin–Kappa Opioid System as a Salience Gatekeeper in Schizophrenia
Varman, D. R. (2026) · Journal of Experimental Neurology · doi:10.33696/neurol.7.128
Mood disruption in heroin abstinence : mechanisms and gene discovery
Ayrancı, G. (2015) · theses.fr (ABES) · doi:10.70675/a956874cz8192z4eb4zb9dez3ceb46a28053
Opioid Antagonists for Hedonic Liberation—Not All Is Over
Шагиахметов, Ф. Ш., Shamakina, I. Y., Kokhan, V. S., & Krupitsky, E. M. (2026) · Future Pharmacology · doi:10.3390/futurepharmacol6020026
Drug discrimination distinguishes pharmacologically distinct κ-opioid receptor agonists in rats
Mori, T., Watanabe, M., Saitoh, T., Ichimaru, Y., Kurihara, M., & Suzuki, T. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179377
BindingDB Entry 50014610: Discovery of an
BindingDB (2022) · UC San Diego · doi:10.7270/q2nz8cg1
BindingDB (2009) · UC San Diego · doi:10.7270/q2bp02bx
BindingDB Entry 50007083: Discovery of a Highly Selective and Potent κ Opioid Receptor Agonist from
BindingDB (2021) · UC San Diego · doi:10.7270/q2vd72rv
BindingDB Entry 50042787: Neoclerodanes as atypical opioid receptor ligands.
BindingDB (2013) · UC San Diego · doi:10.7270/q2x34ztw
BindingDB Entry 50042761: Orvinols with mixed kappa/mu opioid receptor agonist activity.
BindingDB (2013) · UC San Diego · doi:10.7270/q28g8n2q
BindingDB (2012) · UC San Diego · doi:10.7270/q2cz35q9
BindingDB Entry 50028364: Mixed kappa/mu opioid receptor agonists: the 6 beta-naltrexamines.
BindingDB (2010) · UC San Diego · doi:10.7270/q2513z24
Metadata
- Authors
- Walsh, S., Strain, E., Abreu, M., & Bigelow, G.
- Affiliations
- Johns Hopkins University (US)
- AstraZeneca (United States) (US)
- Venue
- Psychopharmacology
- Published
- 2001-09-01
- Volume
- 157
- Issue
- 2
- Pages
- 151-162
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2148208755
- Cited by
- 258
- References
- 51
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 6 · 2023: 5 · 2022: 6 · 2021: 19 · 2020: 9 · 2019: 5 · 2018: 6 · 2017: 7 · 2016: 15 · 2015: 14 · 2014: 6 · 2013: 15 · 2012: 10
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service
- National Institute on Drug Abuse (K05DA000050, K05 DA00050, T32-DA07209, R01 DA10753, R01DA010753, T32DA007209)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- kappa opioid receptor agonists, butorphanol, hydromorphone, opioid pharmacodynamics, sedation, psychotomimetic effects, respiratory depression, polysubstance abuse, opioid analgesics, drug safety
- MeSH terms
- Adult, Analgesics, Opioid, Analysis of Variance, Benzofurans, Butorphanol, Hydromorphone, Dose-Response Relationship, Drug, Double-Blind Method, Female, Heroin Dependence, Humans, Male, Middle Aged, Pilot Projects, Pyrrolidines, Receptors, Opioid, kappa, Cross-Over Studies, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.